Catabasis Pharmaceuticals, Inc.

Release Summary

Catabasis Pharmaceuticals to present CAT-5571, a novel activator of autophagy, as a potential treatment for cystic fibrosis at the 30th Annual North American Cystic Fibrosis Conference.

Catabasis Pharmaceuticals, Inc.